Le Lézard
Classified in: Health
Subject: SVY

Fragile X Syndrome (FXS): Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, Current & Forecasted Market Size from 2017 to 2028 Segmented by 7 Major Markets

DUBLIN, Jan. 27, 2020 /PRNewswire/ -- The "Fragile X Syndrome (FXS) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Fragile X Syndrome in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Fragile X Syndrome from 2017 to 2028 segmented by seven major markets.

Study Period: 2017-2028

Fragile X Syndrome Epidemiology

The Fragile X Syndrome epidemiology division provides insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalence of Fragile X Syndrome in 7MM, Gender-Specific Prevalence of Fragile X Syndrome in 7MM, and Age-Specific Prevalence of Fragile X Syndrome), scenario of Fragile X Syndrome in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to this research, the total prevalent cases of Fragile X Syndrome in the 7MM was found to be 117,962 in 2017. The diagnosed prevalence of Fragile X Syndrome in the 7MM is expected to increase during the study period of 2017-2028 due to increase in the awareness of the condition.

Fragile X Syndrome Drug Chapters

This segment of the Fragile X Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

In the absence of any approved therapy for the treatment for Fragile X Syndrome, the current market size of Fragile X Syndrome is mainly dependent on various specialized therapies, such as speech and language therapy, occupational therapy, physical therapy and drug therapies. The most frequently prescribed therapeutic drug classes are psychotropic drugs, such as antidepressants, stimulants, tranquilizers, and antipsychotics, that are often used to treat disorders such as hyperactivity, anxiety, and inattention.

Interventional services, like speech-language therapy, occupational therapy, physical therapy, special education services, and behavior management are commonly utilized to address specific behaviors and developmental issues, and comorbid conditions, such as ASD, anxiety, attention-deficit/hyperactivity disorder (ADHD), seizures, and others.

Antipsychotic drugs generally are helpful in clinical settings to target irritability, aggression, mood instability, and perseverative behaviors in both male individuals and female individuals with Fragile X Syndrome. Risperidone is the most frequently used antipsychotic drug in the past and was effective clinically, with high response rates for aggressive behavior in older male individuals with Fragile X Syndrome and other irritable, aberrant, and undesired behaviors in young boys with Fragile X Syndrome and autistic traits. Aripiprazole is the second most frequently used atypical antipsychotic agent used in Fragile X Syndrome, with the highest overall response rate for an individual-antipsychotic and the lowest concern about weight gain.

However, these pharmacologic treatments target only the behavioral symptoms and not the cognitive/language impairments or the underlying brain deficits.

Several companies are working robustly on many new therapies, such as BPN14770 (Tetra Therapeutics), Cannabidiol (Zynerba Pharmaceuticals), OV101 (Ovid Therapeutics), Acamprosate (Confluence Pharmaceuticals), and Trofinetide (Neuren Pharmaceuticals) and others. These all are anticipated to enter the Fragile X Syndrome market by 2028.

Fragile X Syndrome Market Outlook

The Fragile X Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to this research, the market of Fragile X Syndrome in 7MM was found to be approximately USD 33.51 Million in 2017.

Fragile X Syndrome market size in the United States accounted for approx. 66% of the total market in 2017. The US led the market in 2017, followed by the EU5 and Japan respectively.

Fragile X Syndrome Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

Currently, the market of Fragile X Syndrome depends on off-label psychotropic drugs, such as antidepressants, stimulants, tranquilizers, antipsychotics and others.

Various therapies are in the late stage of development by various companies such as BPN14770 (Tetra Therapeutics), Cannabidiol (Zynerba Pharmaceuticals), OV101 (Ovid Therapeutics), Acamprosate (Confluence Pharmaceuticals), and Trofinetide (Neuren Pharmaceuticals) for patients with Fragile X Syndrome. All these therapies are expected to enter the market during the forecast period 2019-2028.

Key Topics Covered

1. Key Insights

2. Fragile X Syndrome (FXS): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of FXS in 2017
2.2. Total Market Share (%) Distribution of FXS in 2028

3. Disease Background and Overview: Fragile X Syndrome (FXS)
3.1. Introduction
3.2. Genomics
3.3. Symptoms
3.4. Clinical Features
3.5. Diagnosis
3.6. Fragile X and Newborn Screening
3.6.1. Recommendations for Diagnostic Testing
3.6.2. Differential Diagnosis

4. Epidemiology and Patient Population: Fragile X Syndrome
4.1. Key Findings
4.2. Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM
4.3. United States
4.3.1. Assumptions and Rationale
4.3.2. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United States
4.3.3. Gender-Specific Cases of Fragile X Syndrome (FXS) in the United States
4.3.4. Age-Specific Cases of Fragile X Syndrome (FXS) in the United States
4.4. EU5
4.5. Assumptions & Rationale
4.6. Germany
4.7. France
4.8. Italy
4.9. Spain
4.10. United Kingdom (UK)
4.11. Japan

5. Current Treatment

6. Unmet Need

7. Emerging Drugs
7.1. Key Cross Competition
7.2. Cannabidiol: Zynerba Pharmaceuticals
7.2.1. Product Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Acamprosate: Confluence Pharmaceuticals
7.4. BPN14770: Tetra Therapeutics
7.5. OV101: Ovid Therapeutics
7.6. Trofinetide: Neuren Pharmaceuticals

8. Market Size: Fragile X Syndrome
8.1. Key Findings
8.2. Total Market Size of Fragile X Syndrome in 7MM
8.3. Total Market Size of Fragile X Syndrome by Therapies in 7MM

9. Market Outlook: 7 MM
9.1. United States
9.1.1. The total market size of Fragile X Syndrome in the US
9.1.2. Total Market Size of Fragile X Syndrome by Therapies in the US
9.2. EU5
9.3. Germany
9.4. France
9.5. Spain
9.6. United Kingdom
9.7. Japan

10. Market Drivers

11. Market Barriers

12. KOL Views

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ej2cus

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

These press releases may also interest you

at 16:35
AVROBIO, Inc. , a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today shared an update on its response to the COVID-19 pandemic and a current assessment of the impact on AVROBIO's...

at 16:30
Like so many others, I have been reflecting on what we have lived through for the past few weeks. We have been faced with dozens of challenges and decisions that we haven't had to deal with before in our lives or careers. And these are exactly the...

at 16:30
NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the...

at 16:25
Air Canada said today that due to the unprecedented impact of Covid-19 upon its business, the airline will reduce capacity for the Second Quarter of 2020 by 85%-90% compared to last year's Q2 and will place 15,200 members of its unionized workforce...

at 16:20
Maya Gold & Silver Inc. ("Maya" or the "Corporation") has postponed filing its annual financial statements, management's discussion and analysis and annual information form for the year ended December 31, 2019 (collectively the "2019 annual...

at 16:15
INVO Bioscience, Inc. , a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results...

News published on 27 january 2020 at 09:45 and distributed by: